Is Oscar Health (OSCR) Fully Priced Following Raised 2026 Guidance?

August 29, 2026 - 18:46

Oscar Health (OSCR) has captured renewed attention from investors after reporting what it called record results for the first half of 2026 and subsequently lifting its full-year guidance. The company's stock has been on a notable run, though recent days show some cooling. Shares closed at USD 30.47, reflecting a 4.9 percent decline over the past seven days. That short-term dip, however, comes after a more dramatic upward move: the stock is up 37.07 percent over the last 90 days, and over a three-year horizon, total shareholder return stands at an impressive 363.07 percent.

The raised guidance appears to be the key catalyst behind the recent surge. Management pointed to stronger membership growth, improved medical loss ratios, and better operating efficiency as drivers of the upgraded outlook. For a company that has historically struggled with profitability, the latest numbers suggest a turning point may finally be taking hold. Investors are clearly betting that Oscar's model is scaling in a sustainable way, particularly as it expands into new markets and deepens its partnerships with health systems.

Still, the question remains whether the current valuation already reflects the good news. With the stock up so sharply over the past three months, some analysts are cautious. The 4.9 percent pullback in the last week could be a sign that profit-taking is underway, or it could simply be a pause before another leg higher. The company's ability to maintain its momentum will depend on whether it can keep enrollment growing without letting costs spiral. For now, the market seems willing to give Oscar the benefit of the doubt, but the margin for error is getting thinner at these levels.